About Vasculitis

Microscopic Polyangiitis

Download this page as a PDF

What is Microscopic Polyangiitis?

Microscopic Polyangiitis (MPA) is inflammation of the small and sometimes medium sized blood vessels. In the past MPA was thought to be a type of PAN and patients would have been told they had PAN. It is now recognised that they are separate diseases.

In microscopic polyangiitis it is common for the smallest blood vessels (capillaries) of the lungs and kidneys to be damaged leading to reduced kidney function or kidney failure and breathlessness.

Who are affected?

MPA is commonest in middle aged people and affects both men and women.

What is the aetiology (cause)

The cause of MPA is not yet known

The ANCA antibodies found in most patients with MPA play a role in causing the inflammation of the blood vessels by activating some types of white blood cell. The ANCA antibodies attach to the neutrophils in the blood causing activation. This makes the neutrophil attach to the blood vessel wall and cause damage by release of the chemicals that it usually uses to fight infection. It is not understood why patients develop ANCA antibodies.

What are the symptoms?

Skin ulcer in MPACommon symptoms in MPA are tiredness, loss of appetite and joint and muscle aches. The other symptoms of MPA will depend on the organs involved and will vary markedly between different patients.

Occasionally MPA just affects the kidneys (sometimes called Renal Limited Vasculitis) so that an individual may only begin to feel unwell when the kidney function has deteriorated.

Some symptoms encountered, specific to various systems are:

  • Lungs - breathlessness, wheeze, dry cough or coughing up blood
  • Skin - rashes, ulcers, and necrosis (death of tissue)
  • Eyes - red (blood shot) eyes, painful, dry or gritty eyes, visual loss or other changes in vision
  • Nerves - loss of sensation, weakness, unusual painful symptoms in the hands and feet (hotness, pins and needles or "electric shocks") and rarely paralysis or stroke
  • Bowels - Diarrhoea, bleeding and abdominal pain.

Diagnosis

As with other type of vasculitis the diagnosis depends on the doctor recognising the pattern of symptoms and clinical signs. The ANCA blood test and a biopsy from the kidney or other affected organ are very helpful tests for MPA.

Treatment

Prednisolone (steroid) and cyclophosphamide are often used to get the disease under control in moderate or severe cases. In mild cases where the kidneys are normal milder treatment with prednisolone and methotrexate may be given. If the disease is very severe large doses of methylprednisolone or plasmapheresis (plasma exchange) may also be given. When the disease becomes quiet less toxic drugs are used to keep control which include: azathioprine, methotrexate and mycophenolate mofetil usually in combination with low dose prednisolone.

Rituximab has recently been shown to be effective in some cases of MPA instead of cyclophosphamide although it is not suitable for all patients.

Drugs and Side effects

For information on the main drugs prescribed for Microscopic Polyangiitis see:

For information on other drugs used in the treatment of vasculitis see Glossary of drugs and side effects.

Treatment - Plasma exchange or plasmapheresis

This treatment is sometimes used in patients with severe vasculitis where antibodies in the blood are thought to be important in causing the disease. The treatment involves removing antibodies from the blood using a machine and returning the “cleaned” blood back to the patient. The treatment may necessitate giving blood products to the patient including plasma, albumin or immunoglobulin. It may also involve giving drugs to thin the blood and prevent it clotting in the machine.

For information on plasma exchange:

Prognosis

The overall prognosis in MPA depends on the severity of the disease and the amount of damage that has been done to organs,especially the kidneys, when the disease was active.

Relapses can occur in MPA though less commonly than in some other types of vasculitis and usually require a temporary increase in treatment. It is not clear how long patients with MPA should remain on treatment for and this should be discussed with the doctors looking after the patient on an individual basis.

Key Points

  • MPA is a rare form of vasculitis
  • It often causes severe kidney and lung damage
  • Treatment often requires high dose steroids and cyclophosphamide.

Related Vasculitis Articles

Further reading

Useful links

Our Useful Vasculitis Links page contains contact details for organisations offering help and support for patients with Microscopic Polyangiitis and other vasculitis diseases.

eurordis logo

News

BSR 2018 - a retrospective view

11 May 2018

A retrospective view of the British Society of Rheumatolgy Spring Conference 2018

Vasculitis UK AGM and General Meeting April 2018

11 May 2018

May is Vasculitis Awareness Month

29 Apr 2018

May is Vasculitis Awareness Month

Events

Coffee and a chat in Bristol

24 May 2018

Edinburgh Marathon

27 May 2018

"Brutal" challenge for Georgia

Long-distance cycling for VUK

28 May 2018

Colin Cole is cycling across Britain.

Wing Walk for VUK

03 Jun 2018

Daring walk in memory of Elizabeth

Leicester Vasculitis Support Group Meeting

09 Jun 2018

Copyright © 2018 Vasculitis UK. All Rights Reserved. Whilst we make every effort to keep up to date, any information that is provided by Vasculitis UK should not be a substitute for professional medical advice. Always seek the opinion of your GP or other qualified medical professional before starting any new treatment, or making changes to existing treatment.
Design & Hosting by On Screen